Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma (IRIS)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2012 by IRCCS San Raffaele.
Recruitment status was:  Recruiting
Sponsor:
Information provided by (Responsible Party):
Andres J. M. Ferreri, IRCCS San Raffaele
ClinicalTrials.gov Identifier:
NCT01514344
First received: January 6, 2012
Last updated: January 17, 2012
Last verified: January 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2015
  Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)